EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer

Hannah Christina Puhr iD, Thorsten J Reiter, Matthias Preusser, Gerald W Prager, Aysegül Ilhan-Mutlu iD

Cancers · 22.03.2023 · 15 (6) · 1900

DOI: 10.3390/cancers15061900 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.03.2023. Verfasst von Hannah Christina Puhr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The overall survival expectancy of localized gastroesophageal cancer patients still remains under 5 years despite advances in neoadjuvant and adjuvant treatment strategies in recent years. For almost a decade, immunotherapy has been successfully implemented as a first-line treatment for various oncological diseases in advanced stages. In the case of advanced gastroesophageal cancer, 2021 witnessed several approvals of immune checkpoint inhibitor therapies by different authorities. Although it is still a debate whether this treatment should be restricted to a certain subgroup of patients based on biomarker selection, immunotherapy agents are making remarkable steps in resectable settings as well. The Checkmate-577 study demonstrated significant benefits of nivolumab as an adjuvant treatment for resectable esophageal and gastroesophageal junction tumors and thereby obtained approvals both from U.S. American and European authorities. First results of further potential practice-changing clinical trials are expected in 2023, which might change the treatment armamentarium for resectable gastroesophageal cancers significantly. This review aims to demonstrate the advances of immunotherapy and targeted therapies in treatment of localized gastric, gastroesophageal junction and esophageal tumors and gives a short summary on promising ongoing clinical trials.

Schlagwörter

Stichwörter der Autor:innen

esophageal cancergastric cancerlocalized

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

ORCID-Profile: Hannah Christina Puhr, Aysegül Ilhan-Mutlu

Zitieren

APA

Puhr, H. C., Reiter, T. J., Preusser, M., Prager, G. W., & Ilhan-Mutlu, A. (2023). Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer. Cancers, 15(6), 1900. https://doi.org/10.3390/cancers15061900

Vancouver

Puhr HC, Reiter TJ, Preusser M, Prager GW, Ilhan-Mutlu A. Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer. Cancers. 2023;15(6):1900. doi:10.3390/cancers15061900

BibTeX
@article{Puhr2023,
  author = {Puhr, Hannah Christina and Reiter, Thorsten J and Preusser, Matthias and Prager, Gerald W and Ilhan-Mutlu, Aysegül},
  title = {Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1900},
  doi = {10.3390/cancers15061900}
}
Kostenlos starten →